ARS Pharmaceuticals(SPRY.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
ARS Pharmaceuticals
SPRY.US
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
1.813 T
SPRY.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking230/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-136.40%E
    • Profit Margin-200.00%E
    • Gross Margin53.17%B
  • Growth ScoreD
    • Revenue YoY1.92%C
    • Net Profit YoY-1165.02%E
    • Total Assets YoY-12.14%E
    • Net Assets YoY-73.22%E
  • Cash ScoreC
    • Cash Flow Margin88.43%C
    • OCF YoY1.92%C
  • Operating ScoreD
    • Turnover0.32D
  • Debt ScoreE
    • Gearing Ratio78.68%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M

    TradingView·
    US
    SPRY
    -1.78%
    TradingView·
    US
    SPRY
    -1.78%

    Sector Update: Healthcare Stocks Softer Friday Afternoon

    Fidelity·
    US
    ALMS
    +1.77%
    US
    DXCM
    +2.86%
    US
    SPRY
    -1.78%
    Fidelity·
    US
    ALMS
    +1.77%
    US
    DXCM
    +2.86%
    US
    SPRY
    -1.78%

    ARS Pharmaceuticals shares are trading lower after the company reported mixed Q1 financial results.

    benzinga_article·
    US
    SPRY
    -1.78%
    benzinga_article·
    US
    SPRY
    -1.78%

    ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion

    Tip Ranks·
    US
    SPRY
    -1.78%
    Tip Ranks·
    US
    SPRY
    -1.78%

    ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary

    TradingView·
    US
    SPRY
    -1.78%
    TradingView·
    US
    SPRY
    -1.78%
    © 2026 Longbridge｜Disclaimer